ESTRO 2024 - Abstract Book

S2104

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

Stage I

1080 (96%)

702 (95%)

Stage II-IV

48 (4%)

36 (5%)

Histology

Nodular

726 (64%)

502 (68%)

Infiltrative

185 (16%)

110 (15%)

Morphea

24 (2%)

17 (2%)

Unclassified

193 (18%)

109 (15%)

Field size (tumor+margin)

<2.5 cm

596 (53%)

389 (53%)

≥2.5 cm

532 (47%)

349 (47%)

Dose pr. fraction

3 Gy

739 (65%)

536 (73%)

4.5 Gy

391 (35%)

202 (27%)

Table 1: Patient-, tumor- and treatment characteristics.

Conclusion:

Overall, 96% of patients were satisfied with the cosmetic result six months after hypofractionated kilovoltage therapy for BCC. No impact of fractionation size/schedule could be detected, but field size, age, and current smoking status were associated with a worse professional evaluation score.

Keywords: Basal cell carcinoma, kilovoltage therapy, PROM

1778

Digital Poster

Intraoperative radiotherapy for soft tissue sarcoma: Experience from a Latin American cancer center

Carlos Lehmann-Mosquera 1 , Sara Mendoza-Díaz 2,3 , Juanita Martínez-Villacrés 1 , Paola Rodríguez-Ossa 1 , María Vallejo Ortega 4 , Alex Álvarez-Martínez 2 , Eduardo Guerrero-Lizcano 2 , Carlos Duarte-Torres 1 , Mauricio García-Mora 5 , Javier Ángel-Aristizábal 1 , Sandra Díaz-Casas 1 1 Instituto Nacional de Cancerología, Breast and Soft Tissue Surgery, Bogotá, Colombia. 2 Instituto Nacional de Cancerología, Radiation Oncology, Bogotá, Colombia. 3 Universidad Militar Nueva Granada, Radiation Oncology, Bogotá, Colombia. 4 Instituto Nacional de Cancerología, Epidemiology and Public health, Bogotá, Colombia. 5 Instituto Nacional de Cancerología, Surgical Oncology, Bogotá, Colombia

Purpose/Objective: